Kevin Patrick Moran

CIK: 0001806596

Transaction Breakdown

Open Market Buys (P)1 (20.0%)

High conviction signal

Open Market Sales (S)1 (20.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (20.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

VNDA

Vanda Pharmaceuticals Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

VNDA
Vanda Pharmaceuticals Inc.
Mar 2, 2026
Sale(S)
Direct
42.4K shares at avg. $8.27$351K
VNDA
Vanda Pharmaceuticals Inc.
Feb 18, 2026
Award(A)
Direct
125K shares-
VNDA
Vanda Pharmaceuticals Inc.
Mar 1, 2025
Tax Payment(F)
Direct
26.9K shares at avg. $4.76$128K
VNDA
Vanda Pharmaceuticals Inc.
Feb 21, 2025
Purchase(P)
Direct
2K shares at avg. $4.39$9K
VNDA
Vanda Pharmaceuticals Inc.
Feb 18, 2025
Award(A)
Direct
125K shares-

		Type	Shares	Price		Ownership
Mar 2, 2026	VNDA Vanda Pharmaceuticals Inc.	Sale(S)	42,442	$8.27	$350,821	Direct
Feb 18, 2026	VNDA Vanda Pharmaceuticals Inc.	Award(A)	125,000	-	$0	Direct
Mar 1, 2025	VNDA Vanda Pharmaceuticals Inc.	Tax Payment(F)	26,941	$4.76	$128,239	Direct
Feb 21, 2025	VNDA Vanda Pharmaceuticals Inc.	Purchase(P)	2,000	$4.39	$8,779	Direct
Feb 18, 2025	VNDA Vanda Pharmaceuticals Inc.	Award(A)	125,000	-	-	Direct

1-5 of 5 transactions

About Moran Kevin Patrick

Moran Kevin Patrick (SEC CIK 0001806596) files insider reports with the SEC as SVP, CFO & Treasurer of Vanda Pharmaceuticals Inc. (VNDA).

Signal8 holds 5 ownership filings by Moran Kevin Patrick, all Form 4s, filed between Feb 20, 2025 and Mar 4, 2026. Those filings report 5 transactions, from Feb 18, 2025 to Mar 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Moran Kevin Patrick's filings is in WASHINGTON, DC.

Recent filings by Moran Kevin Patrick

Mar 2, 2026: Open-market sale of VNDA shares (Form 4, code S).
Feb 18, 2026: Grant or award of VNDA shares (Form 4, code A).
Mar 1, 2025: Tax withholding of VNDA shares (Form 4, code F).
Feb 21, 2025: Open-market purchase of VNDA shares (Form 4, code P).
Feb 18, 2025: Grant or award of VNDA shares (Form 4, code A).

Other insiders filing for Vanda Pharmaceuticals Inc. (VNDA)

McGuire Daniel Patrick, SVP, GC and Secretary
Chrousos Phaedra, Director
Duncan Charles Cliff, Director
DUGAN RICHARD W, Director
Ward Anne Sempowski, Director
Honore Tage, Director

How to read Form 4 transaction codes